Browsing Genetics and Epidemiology by author "Dearnaley, David"
Now showing items 1-12 of 12
-
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
Bancroft, EK; Page, EC; Brook, MN; Thomas, S; Taylor, N; et al. (ELSEVIER SCIENCE INC, 2021-10-19)BACKGROUND: Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and ... -
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact.
Macinnis, RJ; Antoniou, AC; Eeles, RA; Severi, G; Al Olama, AA; et al. (WILEY, 2011-07-18)Genome wide association studies have identified several single nucleotide polymorphisms (SNPs) that are independently associated with small increments in risk of prostate cancer, opening up the possibility for using such ... -
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.
Ahmed, M; Dorling, L; Kerns, S; Fachal, L; Elliott, R; et al. (NATURE PUBLISHING GROUP, 2016-05-10)BACKGROUND: Numerous germline single-nucleotide polymorphisms increase susceptibility to prostate cancer, some lying near genes involved in cellular radiation response. This study investigated whether prostate cancer ... -
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital.
Bianchini, D; Lorente, D; Rescigno, P; Zafeiriou, Z; Psychopaida, E; et al. (CIG MEDIA GROUP, LP, 2017-10-01)BACKGROUND: The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa) patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) on ... -
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
Page, EC; Bancroft, EK; Brook, MN; Assel, M; Hassan Al Battat, M; et al. (ELSEVIER, 2019-09-18)BACKGROUND: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 ... -
Patterns of recurrence after prostate bed radiotherapy.
Brand, DH; Parker, JI; Dearnaley, DP; Eeles, R; Huddart, R; et al. (ELSEVIER IRELAND LTD, 2019-12-01)BACKGROUND AND PURPOSE: Prostate bed radiotherapy is a standard treatment after radical prostatectomy. Recent evidence suggests that, for patients with a PSA > 0.34 ng/ml, the radiotherapy treatment volume should include ... -
Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.
Reis Ferreira, M; Khan, A; Thomas, K; Truelove, L; McNair, H; et al. (ELSEVIER SCIENCE INC, 2017-12-01)PURPOSE: To investigate the feasibility of dose escalation and hypofractionation of pelvic lymph node intensity modulated radiation therapy (PLN-IMRT) in prostate cancer (PCa). METHODS AND MATERIALS: In a phase 1/2 study, ... -
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
Mikropoulos, C; Hutten Selkirk, CG; Saya, S; Bancroft, E; Vertosick, E; et al. (NATURE PUBLISHING GROUP, 2018-03-20)This corrects the article DOI: 10.1038/bjc.2017.429. -
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.
Kerns, SL; Fachal, L; Dorling, L; Barnett, GC; Baran, A; et al. (OXFORD UNIV PRESS INC, 2020-02-01)BACKGROUND: A total of 10%-20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk ... -
Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study.
Aladwani, M; Lophatananon, A; Robinson, F; Rahman, A; Ollier, W; et al. (PUBLIC LIBRARY SCIENCE, 2020-09-17)INTRODUCTION: Previous evidence has suggested a relationship between male self-reported body size and the risk of developing prostate cancer. In this UK-wide case-control study, we have explored the possible association ... -
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
Bancroft, EK; Page, EC; Castro, E; Lilja, H; Vickers, A; et al. (ELSEVIER, 2014-09-01)BACKGROUND: Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of ... -
Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer.
Patrikidou, A; Uccello, M; Tree, A; Parker, C; Attard, G; et al. (ELSEVIER SCIENCE LONDON, 2017-10-01)